Genmab A/S, of Copenhagen, and Glaxosmithkline plc, of London, said they received marketing authorization from the European Commission to use Arzerra (ofatumumab), a human monoclonal antibody against CD20, in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukemia who have not received prior therapy and who are not eligible for fludarabine-based therapy.